Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic

16Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P

Cite

CITATION STYLE

APA

Aşkın, Ö., Özkoca, D., Uzunçakmak, T. K., & Serdaroğlu, S. (2021). Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatologic Therapy, 34(2). https://doi.org/10.1111/dth.14746

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free